Status:

UNKNOWN

Analysis of Bronchial Remodeling Using Resonance Magnetic Imaging in Severe Asthmatic childrEn

Lead Sponsor:

University Hospital, Bordeaux

Collaborating Sponsors:

Institut National de la Santé Et de la Recherche Médicale, France

Conditions:

Asthma in Children

Eligibility:

All Genders

6-17 years

Phase:

NA

Brief Summary

This study is a diagnostic imaging pilot study evaluating performance of 3D-Ultrashort Time Echo (3D-UTE) Magnetic Resonance Imaging (MRI) for the diagnosis of bronchial remodeling in children with se...

Detailed Description

Background: Asthma is the most frequent chronic disease in childhood. Severe asthma accounts for only 5% of patients but more than half of the costs of the disease. It is characterized by bronchial re...

Eligibility Criteria

Inclusion

  • Child from 6 to 17 years old
  • Having informed consent signed by the holders of parental authority.
  • Having a diagnosis of severe asthma according to the Global Initiative for Asthma (GINA) 2020;
  • Asthma: chronic inflammatory disease of the airways, defined mainly by respiratory symptoms such as wheezing, dyspnea, chest tightness and / or cough, which may vary in time and intensity associated with a limitation also varying in the time of expiratory flow.
  • Severe asthma: asthma which requires treatment with inhaled corticosteroids in high doses plus a second long-acting bronchodilator type controller, to maintain control of symptoms and / or whose control worsens if this treatment is reduced and / or which remains uncontrolled despite this treatment.
  • Having to carry out as part of the current care a functional respiratory exploration;
  • Should require as part of the routine care of a bronchial fibroscopy.

Exclusion

  • Patient without affiliation or not benefiting from a social security scheme;
  • Patient being in a period of relative exclusion from another protocol;
  • Patient born before 36 weeks of amenorrhea;
  • Patient with a documented history of pulmonary fibrosis, primary pulmonary arterial hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections (hepatitis, HIV);
  • Patient presenting with an exacerbation of asthma requiring systemic corticosteroids within the previous 4 weeks;
  • Patient with any dental, nasopharyngeal or bronchial infection with fever (\> 39 ° C) requiring systemic antibiotics within the previous 4 weeks
  • Patient with a contraindication to MRI:
  • Abdominal perimeter greater than 200 cm;
  • Claustrophobia or inability to lie still for 12 minutes;
  • Have a pacemaker or implantable defibrillator, intraocular metallic foreign body, intracranial metal clip, a pre-6000 Starr-Edwards type heart valve prosthesis, or a biomedical device such as an insulin pump or neurostimulator, cochlear implant and metal patch.
  • Patient with a contraindication to anesthesia;
  • Patient with a contraindication to bronchial fibroscopy following:
  • Abnormal hemostasis assessment;
  • Subject with cardiac pathology.

Key Trial Info

Start Date :

June 8 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 30 2025

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05419622

Start Date

June 8 2023

End Date

August 30 2025

Last Update

June 9 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

CHU de Bordeaux - Explorations Fonctionnelles

Bordeaux, France, 33000

2

Centre Hospitalier de Saintonge

Saintes, France, 17100